Iressa proves just as effective as chemotherapy for lung cancer

November 21, 2008

HOUSTON - Gefitinib, also known as Iressa, the once-promising targeted therapy for the treatment of non-small cell lung cancer, has proven as effective as chemotherapy as a second-line therapy for the disease with far fewer side effects, according to an international Phase III clinical trial, led by researchers at The University of Texas M. D. Anderson Cancer Center.

However, in contrast to earlier Iressa findings, the study showed that there was no additional survival benefit for patients who expressed an elevated level of the epidermal growth factor receptor (EGFR) mutation.

The Iressa in Non-small cell lung cancer Trial Evaluating REsponse and Survival versus Taxotere (INTERST) study, published today in The Lancet, represents a paradigm shift for the treatment of the disease, according to lead author Edward S. Kim, M.D., assistant professor in M. D. Anderson's Department of Thoracic Head and Neck Medical Oncology. It marks the first time in lung cancer that an oral pill has proven as effective as chemotherapy in a head-to-head trial.

"This is the largest study in lung cancer comparing an oral biologic therapy to chemotherapy, and shows, for the first time, that an oral biologic therapy is just as effective as chemotherapy," said Kim, the study's corresponding author. "Based on our findings, I'm hopeful that Iressa can return as a treatment for lung cancer in the United States, offering this some patients a therapy with far fewer side effects."

The study also should offer both physicians and patients some confidence in another biological oral therapy, erlotinib, commercially known as Tarceva, that hits similar targets as Iressa and is commercially available for the treatment of lung cancer in the second line setting, explained Kim.

To best appreciate these findings, it's important to remember Iressa's history, said Kim. Iressa, a once-daily, oral tablet, was the first in a new class of anti-cancer drugs known as EGFR tyrosine kinase inhibitors (TKI) to become commercially available after two Phase II trials found the drug to be efficacious. Iressa was fast-tracked to the FDA and received approval May 5, 2003 as a single agent treatment for patients whose advanced lung cancer had continued to progress despite treatment with platinum-based and docetaxel chemotherapy.

However, in 2005, a large randomized lung cancer study reported that Iressa failed to significantly improve survival in patients with non-small cell lung cancer when compared to placebo. Ultimately, the drug's labeling was altered by the FDA; only cancer patients who had already taken the medicine and whose physicians believed it was helping them were allowed to receive the drug. No new lung cancer patients in the United States were given the drug after this time. However, Iressa remained an available therapy in other countries around the world.

Just prior to these negative findings, the INTEREST study began to enroll patients in 2004. Because of the negative data, INTEREST, an FDA-mandated study, was halted in the United States but continued in other parts of the world.

The Phase III international study enrolled 1,466 lung cancer patients from 149 centers in 24 countries. Of those enrolled, 1,433 were evaluable. All had either locally advanced or metastatic disease and had been previously treated for their cancer. Patients were randomized to receive either Iressa (250 milligrams daily) or docetaxel (75 mg/m2) every three weeks. The study had two primary survival endpoints: in all treated patients and in those whose tumors had high EGFR gene copy number, explained Kim.

When comparing all treated patients, median overall survival for those receiving Iressa was 7.6 months and one-year survival was 32 percent, compared to 8 months and a 34 percent one-year survival for those taking chemotherapy. In an assessment of quality of life, Iressa patients experienced far fewer side effects, with the most common being a rash and diarrhea. In contrast, patients taking docetaxel experienced low blood count, infection, and hair loss.

In the subgroup of 174 patients with a high EGFR gene copy number, median overall survival in the Iressa arm was 8.4 months and one-year survival was 32 percent, versus 7.5 months overall survival and a one-year survival rate of 35 percent for those taking chemotherapy.

Tissue samples were evaluable for at least one biomarker in 453 patients. In an additional analysis of the biomarkers EGFR and K-ras mutations, the study indicates that both mutations are overall prognostic survival markers for lung cancer, but not predictive to treatment with either therapy.

"Our study found that patients who received Iressa and whose tumors had EGFR mutations will have an improved response rate and progression-free survival compared to docetaxel, but overall survival was similar in both treatment groups. In contrast, the K-ras gene mutation proved to be an overall poor prognostic marker, with both treatment arms doing poorly," said Kim.

"As lung cancer researchers, our mandate is to focus on finding appropriate biomarkers for the disease so ultimately, we can begin to tailor therapies for lung cancer patients based on their individual tumor characteristics."

University of Texas M. D. Anderson Cancer Center

---

---

	Johns Hopkins Patients' Guide to Lung Cancer by Justin F. Klamerus (Author), Julie R. Brahmer (Author), David S Ettinger (Author) Johns Hopkins Patients' Guide to Lung Cancer is a concise, easy-to-follow how to guide that puts you on the path to wellness by explaining lung cancer treatment from start to finish. It guides you through the overwhelming maze of treatment decisions, simplifies the complicated schedule that lies ahead, and performs the task of putting together your plan of care in layman's terms. Empower yourself with accurate, understandable information that will give you the ability to confidently participate in the decision making about your care and treatment.
	Lung Cancer: A Guide to Diagnosis and Treatment by Walter J. Scott MD (Author) What is my prognosis? What are my treatment options? Which therapies would be the most effective for my stage of lung cancer? These and other frequently asked questions are addressed in this crucial reference designed to help patients educate themselves and obtain the best possible treatments. The completely revised second edition has been updated to include a discussion of the movement towards customized chemotherapy; treatment options for early-stage lung cancer including minimally invasive surgery; and the most promising treatments, among them multimodality therapy—a combination of surgery, chemotherapy, and radiation. Dr. Scott also surveys tests for early detection of lung cancer, talks about the importance of cancer staging, examines alternative treatments, and offers advice on...
	Lung Cancer: Myths, Facts, Choices--and Hope by Claudia I. Henschke (Author), Peggy McCarthy (Author), Sarah Wernick (Contributor) An authoritative book with new lifesaving strategies for those at risk and those already diagnosed.Lung cancer kills more women than breast cancer, more men than prostate cancer. This authoritative book presents new lifesaving strategies for those already diagnosed and those at risk (including ex-smokers). Lung cancer is deadly because it's usually found late. Dr. Claudia Henschke's groundbreaking research on early diagnosis, published in Lancet, made headlines worldwide. Now, for the first time, she offers specific recommendations based on her latest findings: who needs to be checked and how to get tested. People with lung cancer often are told, "Nothing can be done." Not so! Dr. Henschke and coauthor Peggy McCarthy, a leading patient advocate, provide...
	Be A Survivor: Lung Cancer Treatment Guide by Vladimir Lange MD (Author) This much needed lung cancer resource is developed in consultation with a large national team of experts featuring: * Candid testimonials by survivors * Straightforward, easy-to-understand language * Objective and up-to-date information * Beautiful color photos and graphics * An empowering message of HOPE. The book addresses each step in the diagnosis, staging, treatment and recovery process, and includes a chapter on end-of-life issues, and a section specifically for the patient's partner or caregiver.
	Principles and Practice of Lung Cancer: The Official Reference Text of the International Association for the Study of Lung Cancer (IASLC) (Pass, Lung Cancer) by Harvey I. Pass (Editor), David P. Carbone (Editor), David H. Johnson (Editor), John D. Minna (Editor), Giorgio V. Scagliotti (Editor), Andrew T. Turrisi (Editor) Thoroughly revised and updated, this Fourth Edition is the most comprehensive, current reference on lung cancer, with contributions from the world's foremost surgeons, radiation oncologists, medical oncologists, pulmonologists, and basic scientists. Coverage includes complete information on combined modality treatments for small cell and non-small cell lung cancer and on complications of treatment and management of metastases. Emphasis is also given to early detection, screening, prevention, and new imaging techniques. This edition has expanded thoracic oncology chapters including thymus, mesothelioma, and mediastinal tumors, more detailed discussion of targeted agents, and state-of-the-art information on newer techniques in radiotherapy. Other highlights include more international...
	100 Questions & Answers About Lung Cancer, Second Edition by Karen Parles (Author), Joan H. Schiller (Author), Amy Cipau (Author) Empower yourself! No one with lung cancer needs to be alone in their fight against this disease. 100 Questions & Answers About Lung Cancer, Second Edition enables patients and their families to seek our the best treatment possible for early detection of lung cancer. Providing both the doctor s and patient s point of view, this book is a complete guide to understanding treatment options, post-treatment quality of life, sources of support, and much more. Through 100 Questions & Answers About Lung Cancer, Second Edition, expert authors use their experiences with patients to provide support and hope to the tens of thousands of people coping with this disease.
	How to Survive Lung Cancer - A Practical 12-Step Plan by Michael Lloyd (Author) Written by a lung cancer survivor who understands what it takes to beat the odds, this book offers unparalleled hope and direction for anyone facing this illness. It is filled with specific exercises and techniques to promote healing and reverse side effects by taking a pro-active approach in helping to restore your mind, body and spirit to an optimum state of health. Endorsed by a Lung Cancer Specialist and Associate Professor at Harvard Medical School, this book combines what the doctors tell you with critical information they don't tell you. Visit www.SurviveLungCancer.com for chapter summaries.
	Lung Cancer: Causes, Symptoms, Signs, Diagnosis, Treatments, Stages Of Lung Cancer - Revised Edition - Illustrated by S. Smith by Department of Health and Human Services (Author), National Institutes of Health (Author), National Cancer Institute (Author), S. Smith (Editor), S. Smith (Editor)
	Lung Cancer: A Multidisciplinary Approach to Diagnosis and Management (Current Multidisciplinary Oncology) by Kemp Kernstine MD PhD (Editor), Karen Reckamp MD MS (Editor), Charles Thomas Jr. MD (Editor) Over the course of the last decade, the treatment of lung cancer has evolved quite rapidly. New scientific and clinical advances have modified the standard of care and led to improved patient outcomes. At the same time, the treatment of lung cancer has become increasingly complex, requiring the comprehensive review and assessment of multiple issues, genetics, radiology, surgery, reconstruction, chemotherapy, and more. As a result the harmony and open communication between these specialties facilitated by a multidisciplinary team approach are crucial in providing the best care to patients and ensuring successful treatment. Lung Cancer: A Multidisciplinary Approach to Diagnosis and Management, written by a multidisciplinary team of authors representing a range of disciplines, is a valuable...
	Voices of Lung Cancer: The Healing Companion: Stories for Courage, Comfort and Strength (Voices Of series) by The Healing Project (Editor), S. Epatha Merkerson (Editor) Provided by the patients, their friends, families, and caregivers of those diagnaosed with lung cancer, these very personal stories offer inspired insight into the ways families and professionals care for both themselves and the patient, gain a deeper understanding of the relationships, and learn to come to terms with the end of life. Included are essays by medical experts about the science of lung cancer, current treatments, choosing the right doctors, and what the future holds for the next generation of patients.